The value of neoadjuvant chemotherapy in localized high-risk soft-tissue sarcoma of the extremities and trunk
A partir de données de divers essais cliniques, ces deux articles débattent de l'intérêt de la chimiothérapie néoadjuvante pour traiter les patients atteints d'un sarcome localisé des tissus mous
The role of neoadjuvant chemotherapy in treating localized soft-tissue sarcoma (STS) has been controversial for more than 30 years.1 The rarity and heterogeneity of these tumors have resulted in conflicting trial results that have failed to provide a definitive answer, with some of the larger trials reporting no benefit and other, smaller trials showing a benefit for chemotherapy.2-6
JAMA Oncology 2018